Year: 2023

Global Automotive Airbag Silicone Market Size to Reach USD 1,301.37 Million in 2032 | Emergen Research

Written by Customer Service on November 2, 2023. Posted in Mergers And Acquisitions.

Increasing installation of airbags in commercial vehicles and increasing passenger vehicle sales and production are some of key factors driving global automotive airbag silicone market growth Vancouver, Nov. 02, 2023 (GLOBE NEWSWIRE) — The global automotive airbag silicone market size reached USD 237.5 Million in 2020 and is expected to register a CAGR of 15.4% during the forecast period, according to latest analysis by Emergen Research. Global automotive airbag silicone market revenue is expected to increase significantly during the forecast period due to increasing installation of airbags in passenger and commercial vehicles. Furthermore, increasing deployment of stringent safety regulations by governments of various countries is expected to further support growth of the global automotive airbag silicone market going ahead. However,...

Global Sports Technology Market Size to Reach USD 79.31 Billion by 2032 | Emergen Research

Written by Customer Service on November 2, 2023. Posted in Mergers And Acquisitions.

Rapid adoption of technologically advanced solutions in all fields of sport is driven by urgent need for recovery across the sports industry post the global COVID-19 lockdown Vancouver, Nov. 02, 2023 (GLOBE NEWSWIRE) — The global sports technology market is projected to reach a market size of USD 79.31 Billion by 2032, according to latest analysis by Emergen Research. This growth can be attributed to increasing adoption of advanced technologies for a range of applications in the world of sports. The COVID-19 pandemic and lockdown has severely impacted the global sports industry as all sporting events and stadiums remained under lockdown. A vast majority of athletes and players have suffered due to inability to train and stay in top shape. As a result, 2021 is a pivotal year for athletes, broadcasters, teams, and fans around the...

ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting

Written by Customer Service on November 2, 2023. Posted in Public Companies.

Presentations to highlight clinical utility of ZYNLONTA® (loncastuximab tesirine-lpyl) as a single agent and in combination Oral presentation to include initial results of investigator-initiated Phase 2 study evaluating ZYNLONTA in combination with rituximab in patients with r/r follicular lymphoma LAUSANNE, Switzerland, Nov. 02, 2023 (GLOBE NEWSWIRE) — ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on ZYNLONTA® (loncastuximab tesirine-lpyl) have been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting, which will be held in San Diego, California from December 9-12, 2023. “We look forward to sharing insights from the growing body of research supporting the clinical utility of ZYNLONTA as a single agent and in combination with other treatments at the 65th ASH Annual Meeting,”...

Biostax Announces the Appointment of Ms. Mary Clay Caperton to its Board of Directors

Written by Customer Service on November 2, 2023. Posted in Public Companies.

Orlando, FL, Nov. 02, 2023 (GLOBE NEWSWIRE) — Biostax Corp (OTC Pink: BTAX) (“Biostax”), a hub and spoke biotech development engine, announces the appointment of Ms. Clay Caperton to its Board of Directors. Ms. Caperton stands as the esteemed founder and CEO of BOSACS Holding, LLC, boasting a rich history in the dynamic realm of sports management and has maintained a fervent dedication to the not-for-profit sector spanning over two decades. Her impactful journey has seen her contribute significantly to esteemed organizations, including the Bon Secours Foundation Board, Trinity Episcopal School Board of Trustees, Boys & Girls Clubs of Richmond, St. Mary’s Episcopal School Board of Trustees, Soar365, and United Way Services of Greater Richmond. In her remarkable career, Ms. Caperton has demonstrated exceptional prowess as a...

New Clinical Data on OPKO Health’s RAYALDEE® (ER Calcifediol) Presented at Kidney Week 2023

Written by Customer Service on November 2, 2023. Posted in Public Companies.

MIAMI, Nov. 02, 2023 (GLOBE NEWSWIRE) — OPKO Health, Inc. (NASDAQ: OPK) presented late-breaking clinical data on RAYALDEE® extended-release calcifediol (ERC) at the American Society of Nephrology (ASN) Kidney Week in Philadelphia today. These data, presented in a poster titled “Control of Secondary Hyperparathyroidism with Extended-release Calcifediol is Associated with Slower CKD Progression” (#TH-PO1152), indicate that early, sustained and effective treatment of secondary hyperparathyroidism (SHPT) with RAYALDEE is associated with significantly slower progression of chronic kidney disease (CKD) in pre-dialysis patients. The poster is available on OPKO’s website here. Progressive changes in estimated glomerular filtration rate (eGFR) were examined post-hoc in 166 patients with vitamin D insufficiency, SHPT and stage 3 or 4 CKD...

Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting

Written by Customer Service on November 2, 2023. Posted in Public Companies.

– Analysis further supports obesity-associated dysregulated aldosterone as an endotype predictive of enhanced response to lorundrostat treatment in patients with uncontrolled or treatment-resistant hypertension – –Endotype identification from Target-HTN may represent a shift towards targeted, precision-directed therapy for hypertension management in future treatment paradigm – – Ongoing Advance-HTN trial, first of two pivotal studies, will further characterize hypertensive endotype for enhanced response to lorundrostat treatment – RADNOR, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today presented a new...

JPMorgan ETFs (Ireland) ICAV: Sub-Fund Liquidation

Written by Customer Service on November 2, 2023. Posted in Dividend Reports And Estimates.

DUBLIN, Ireland, Nov. 02, 2023 (GLOBE NEWSWIRE) — JPMorgan ETFs (Ireland) ICAV Liquidation of JPMorgan ETFs (Ireland) – RMB Ultra-Short Income UCITS ETF – effective from 12 December 2023 This is to notify you that the JPMorgan ETFs (Ireland) – RMB Ultra-Short Income UCITS ETF (the “Sub-Fund”) in which you hold shares will be liquidated. Your Sub-Fund will bear securities transaction costs only; all other costs associated with the liquidation will be paid by the management company. To help ensure an orderly and efficient liquidation process, your Sub-Fund may begin liquidating holdings in the period leading up to the liquidation date. In relation to distributing share classes only, the final dividend distribution will be paid on 7 December 2023. Any further accrued income at the time of liquidation...

IMPORTANT MESSAGE TO NYMOX SHAREHOLDERS: NYMOX Cautions Against Unauthorized Improper Shareholder Meeting and Unauthorized Unregistered Solicitations

Written by Customer Service on November 2, 2023. Posted in Public Companies.

IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) — The following is Nymox’s response to an unauthorized shareholder meeting: Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company” or “Nymox”) warns its shareholders that false and manipulative behavior is involved in attempts to hold what the Company considers an unlawful, unauthorized, and improper “shareholders meeting” that does not have the support of the Company or anyone currently associated with the Company. Shareholders who are listed on Nymox’s proprietary shareholders list have been solicited and contacted by a proxy solicitation company in New York. That Company shareholder list is considered by the Company to be proprietary information that has been stolen by the individuals attempting to have this “shareholders meeting.” Those individuals...

Wallbridge Closes Previously Announced Private Placement of Common Shares

Written by Customer Service on November 2, 2023. Posted in Public Companies.

TORONTO, Nov. 02, 2023 (GLOBE NEWSWIRE) — Wallbridge Mining Company Limited (TSX:WM, OTCQX:WLBMF) (“Wallbridge” or the “Company”) is pleased to announce that it has completed the previously announced non-brokered private placement with Agnico Eagle Mines Limited (“Agnico”) of 7,926,277 common shares in the capital of the Company at a price of $0.11 per common share (the “Private Placement”). The Private Placement was undertaken pursuant to certain participation rights set out in a pre-existing participation agreement between the Company and a predecessor of Agnico. With the net proceeds from the Private Placement, together with the $9.4 million of gross proceeds from the flow through private placement that closed on October 26, 2023, the Company expects to have a year end cash balance of approximately $25 million, which it anticipates...

Global HD Maps for Autonomous Vehicles Market to Reach Value of USD 53.71 Billion by 2032 | Emergen Research

Written by Customer Service on November 2, 2023. Posted in Mergers And Acquisitions.

Rising trend of autonomous driving and integration of more advanced HD maps in new vehicles are factors driving global HD maps for autonomous vehicles market growth Vancouver, Nov. 02, 2023 (GLOBE NEWSWIRE) — The global HD maps for autonomous vehicles market is projected to reach a market size of USD 53.71 Billion at a steady CAGR of 34.3% in 2032, according to latest analysis by Emergen Research. This steady revenue growth can be attributed to increasing need for safer, cleaner, and less congested roads in countries across the globe. Relaxation of stringent laws and regulations for autonomous vehicles to encourage adoption and ease traffic congestion is a key factor driving demand. Continuous development and adoption of more advanced technologies such as Artificial Intelligence and 5G in the automotive field is further supporting...

Year: 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals